Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment.

Nathan A UngerleiderSonia G RaoAshkan ShahbandiDouglas YeeTianhua NiuWesley D FreyJames G Jackson

Published in: Breast cancer research : BCR (2018)

The poor survival of chemotherapy-treated patients with TP53 wild-type tumors may be improved by strategies to eliminate senescent cells, including the addition of hormone therapy when appropriate.

Keyphrases

wild type
induced apoptosis
free survival
cell cycle arrest
oxidative stress
locally advanced
endoplasmic reticulum stress
stem cells
signaling pathway
cell death
combination therapy
replacement therapy
young adults
pi k akt